Quick answer: Therapeutic peptides — short amino acid chains (typically 2–50 amino acids) with specific biological signaling activity — represent one of the fastest-growing areas of functional and regenerative medicine. Unlike small-molecule drugs that broadly inhibit or activate receptors, peptides work through physiological signaling pathways with high receptor specificity and typically favorable safety profiles. Key categories include growth hormone secretagogues (CJC-1295/Ipamorelin), tissue repair peptides (BPC-157, TB-500/Thymosin Beta-4), immune modulators (Thymosin Alpha-1), and metabolic peptides (Semaglutide/GLP-1 class).
Growth Hormone Secretagogues: Restoring the GH-IGF-1 Axis
Growth hormone (GH) secretion peaks in puberty and declines approximately 14% per decade after age 30 — by age 60, GH output is approximately 25% of peak levels, with IGF-1 (the primary GH mediator) declining proportionally. This “somatopause” contributes to reduced muscle mass, increased visceral fat, impaired bone density, reduced cognitive function, poorer sleep quality, and diminished tissue repair capacity.
Growth hormone secretagogues (GHS) stimulate the pituitary to release GH through the ghrelin receptor (GHSR) pathway — distinct from exogenous GH administration, they work with the body’s existing pulsatile GH secretion pattern rather than replacing it. This is physiologically important: the pulsatile nature of GH release (approximately 5–9 pulses per day, largest pulse during slow-wave sleep) is critical for metabolic effects and IGF-1 production. Continuous GH administration (exogenous HGH) blunts this pulsatility.
CJC-1295 (Modified GRF 1-29): A GHRH (Growth Hormone Releasing Hormone) analogue — it mimics hypothalamic GHRH to stimulate pituitary GH release. CJC-1295 has a DAC (Drug Affinity Complex) modification that extends its half-life from minutes (native GHRH) to approximately 8 days through albumin binding — enabling weekly or twice-weekly subcutaneous injection. Studies: Teichman et al. (2006, Journal of Clinical Endocrinology & Metabolism): single injection of CJC-1295 produced dose-dependent GH increases peaking at 2 hours, with sustained IGF-1 elevation for 6–7 days. In 28-day repeat-dosing studies, CJC-1295 (2mg twice weekly) increased mean GH levels by 2–10x and IGF-1 by 1.3–1.7x from baseline without tachyphylaxis.
Ipamorelin: A selective GHSR (ghrelin receptor) agonist — the first GHS demonstrated to be truly selective for GH release without significant cortisol, prolactin, or ACTH stimulation (which are common side effects of first-generation GHSs like GHRP-2 and GHRP-6). Raun et al. (1998, European Journal of Endocrinology): Ipamorelin produced potent, dose-dependent GH release without the cortisol/ACTH side effects of GHRP-2. Clinical: Ipamorelin 100–300mcg subcutaneous injection stimulates a GH pulse within 30–60 minutes, with peak duration approximately 3 hours. It is typically combined with CJC-1295 (combined as “CJC/Ipamorelin”) to amplify the GH pulse through simultaneous GHRH and GHSR activation — producing synergistic GH release (Bowers 1993 established that GHRH + GHS combination is dramatically more potent than either alone).
Tesamorelin (FDA-approved GHRH analogue): Approved for HIV-associated lipodystrophy (Egrifta) — well-established clinical data in humans: significantly reduces visceral adipose tissue (14% reduction vs. 1% placebo in pivotal trials), improves triglycerides and apoB, and increases IGF-1. The off-label use in non-HIV aging adults leverages the same adipolytic and anabolic properties. Considered the most rigorously studied peptide in the GHS class from a regulatory standpoint.
BPC-157: The “Body Protection Compound” for Tissue Repair
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice. It is among the most extensively studied peptides in the research literature — with over 500 peer-reviewed publications, almost entirely in animal models. Despite its extensive preclinical evidence and widespread clinical use in functional medicine, BPC-157 has not completed Phase III FDA approval trials and is currently a compound research peptide.
Mechanisms: BPC-157 operates through multiple interconnected pathways: (1) Angiogenesis induction — BPC-157 dramatically accelerates new blood vessel formation via VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) activation — Sikiric et al. multiple studies demonstrate up to 4x faster wound healing attributed to superior vascularization; (2) Nitric oxide pathway modulation — both NO-dependent (EGF receptor activation, VEGF pathway) and NO-independent mechanisms contribute to tissue repair; (3) Tendon and ligament healing — BPC-157 upregulates the expression of tendon-specific growth factor (type I collagen, tenascin-C) and significantly accelerates tendon-to-bone healing in multiple rodent models (Achilles tendon, rotator cuff, ACL); (4) Gut epithelial repair — the original therapeutic context: BPC-157 was isolated from gastric juice and accelerates healing of GI ulcers, fistulas, and inflammatory bowel disease lesions in rodent models; (5) Neuroprotection — BPC-157 reduces neurological damage in traumatic brain injury models, and promotes peripheral nerve regeneration via EGR-1 transcription factor activation.
Clinical use patterns (based on extensive practitioner experience, limited human RCT data): tendinopathy and ligament injuries (2–4mg/day orally or 250mcg–500mcg subcutaneous injection near injury site), inflammatory bowel disease (250mcg–500mcg subcutaneous, or 2–4mg oral for gut-specific effects), neurological recovery post-TBI or peripheral neuropathy (subcutaneous 250mcg BID). Outstanding human trial data remains the primary gap in the BPC-157 evidence base, despite >25 years of rodent research consistently demonstrating safety and efficacy.
Thymosin Beta-4 (TB-500) and Immune-Modulating Peptides
Thymosin Beta-4 (TB-4) is a naturally occurring 43-amino acid peptide ubiquitous in virtually all human cells at high concentrations. Its primary physiological function is G-actin sequestration — TB-4 binds actin monomers, controlling the pool of free actin available for filament formation. This actin-regulatory function makes TB-4 essential for cell motility, wound healing, tissue regeneration, and angiogenesis. TB-500 is a synthetic fragment of TB-4 corresponding to the actin-binding domain (amino acids 17-23), believed to be the primary bioactive sequence for systemic regenerative effects.
Clinical and research applications: cardiac protection (Bock-Marquette 2004, Nature: TB-4 administration after myocardial infarction activated cardiac progenitor cells and significantly improved cardiac function in mice), hair follicle activation (Tb-4 promotes hair stem cell migration and follicle growth in alopecia), neurological recovery (reduces neuroinflammation and promotes oligodendrocyte differentiation in MS models — Kurtz 2008), and anti-inflammatory effects (TB-4 reduces TNF-α and IL-6 production). Typical clinical use: 500mcg–2mg subcutaneous injection 2–3x weekly for 6–12 weeks, often combined with BPC-157 for synergistic connective tissue repair.
Thymosin Alpha-1 (TA1, Zadaxin): A 28-amino acid thymic peptide that modulates innate and adaptive immunity. FDA-approved in 70+ countries (not yet in USA) for hepatitis B, hepatitis C, and as adjuvant in cancer and infection. Mechanisms: promotes Th1 immune response (enhancing cellular immunity — critical for viral clearance and anti-tumor immunity), activates dendritic cells and NK cells, increases CD4+ helper T cell function, and upregulates MHC I antigen presentation. Clinical applications in functional medicine: chronic viral infections (EBV, CMV, HHV-6), post-COVID immune dysfunction, recurrent infections suggesting immune deficiency, as adjuvant to cancer immunotherapy. Typical dose: 1.6mg subcutaneous 2x weekly (the dose used in approved hepatitis trials).
GLP-1 Agonists: From Metabolic Medicine to Longevity Frontier
Glucagon-Like Peptide-1 (GLP-1) receptor agonists — semaglutide (Ozempic/Wegovy), liraglutide (Saxenda/Victoza), tirzepatide (Mounjaro/Zepbound, dual GIP+GLP-1) — are the most transformative pharmaceutical class of the last decade for metabolic medicine. While the weight loss headlines dominate media coverage, functional medicine practitioners recognize GLP-1 agonists as genuinely pleiotropic therapies with effects extending far beyond appetite regulation.
GLP-1 receptors are expressed not only in pancreatic beta cells and hypothalamus (the appetite/insulin secretion effects) but also in cardiac myocytes, vascular endothelium, brain (hippocampus, cortex), kidney, and immune cells. SUSTAIN-6 (semaglutide 1mg weekly vs. placebo, n=3,297, 2 years) and LEADER (liraglutide vs. placebo, n=9,340, 3.5 years) demonstrated significant cardiovascular benefit — 26% and 13% reduction in 3-point MACE respectively — in patients with established cardiovascular disease and T2DM. The SELECT trial (semaglutide 2.4mg vs. placebo, n=17,604, ~33 months, non-diabetic obese patients with established CVD): 20% reduction in MACE — the first demonstration of CV benefit from a weight loss drug in a non-diabetic population.
Beyond CV: emerging data for GLP-1 agonists in Alzheimer’s disease (EVOKE trial — semaglutide in early AD, results pending 2025), Parkinson’s disease (SPARK trial — liraglutide in PD), non-alcoholic steatohepatitis (NASH — GLP-1 produces 59–72% NASH resolution in pivotal trials, ESSENCE trial semaglutide), alcohol and addiction reduction (GLP-1 receptors in the mesolimbic reward pathway suppress addictive behaviors — case series from Yale), and autoimmune inflammation (GLP-1 reduces TNF-α and IL-6 in adipose tissue macrophages, potentially modulating autoimmune disease). The Longevity community has begun investigating GLP-1 agonists as potential aging-modifiers — through insulin sensitization, reduced mTOR signaling, and anti-inflammatory effects — though human longevity data is 10–15 years from maturity.
Peptide Safety, Regulatory Status, and Clinical Considerations
The peptide regulatory landscape is complex and evolving. In 2023–2024, the FDA reclassified many popular research peptides (including BPC-157, Ipamorelin, CJC-1295, TB-500) from “bulk drug substances” eligible for compounding to “withdrawn” from the compounding list — meaning compounding pharmacies cannot produce them for clinical use in the U.S. without specific exemptions. This has created significant disruption in functional medicine peptide prescribing.
GLP-1 agonists (semaglutide, tirzepatide) remain available as FDA-approved drugs but were compounded extensively during nationwide shortages in 2022–2024; the shortage designations were removed in 2024–2025, ending most compounding exemptions. Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy — can be prescribed off-label for other indications by licensed physicians. Thymosin Alpha-1 is FDA-designated orphan drug status for several indications and can be obtained through licensed compounding pharmacies. The landscape requires practitioners to work with specialized compounding pharmacies with PCAB accreditation and to stay current with FDA policy changes.
Safety profile overview: GHS peptides — generally well-tolerated; side effects include water retention, carpal tunnel symptoms (at high GH levels), and injection site reactions; IGF-1 monitoring recommended to avoid supraphysiologic levels (theoretical insulin resistance and proliferative concerns at excessive IGF-1). BPC-157 — extensive rodent safety data with no significant toxicology findings at therapeutic doses; no serious adverse events reported in human experiential literature; limited formal human safety trials. GLP-1 agonists — well-characterized safety profiles from large RCTs: nausea (40–50%, dose-dependent, usually resolves 4–8 weeks), rare pancreatitis (clinical monitoring), theoretical thyroid C-cell effects (rodent data, not confirmed in humans), gallbladder events (increased risk with rapid weight loss), muscle loss without resistance training (critical to maintain exercise regimen).
Peptide Therapy at The Private Practice
At The Private Practice, peptide therapy is integrated into our comprehensive functional medicine framework — GHS peptides are evaluated alongside testosterone optimization, GLP-1 agonists within our metabolic health and insulin resistance protocols, and tissue repair peptides in our musculoskeletal and pain management approach. All peptide prescriptions require medical evaluation, appropriate indication, baseline and follow-up lab monitoring, and informed consent regarding investigational or off-label status.
Frequently Asked Questions
Are peptides the same as steroids?
No — peptides and anabolic steroids are fundamentally different classes of compounds with entirely different mechanisms, safety profiles, and legal status. Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone that bind androgen receptors directly and suppress the HPG axis — producing spermatogenesis suppression, virilization, hepatotoxicity (oral 17α-alkylated forms), and cardiovascular effects including LVH and lipid dysfunction. Peptides are amino acid chains that work through physiological receptor signaling (GH secretagogues stimulate the body’s own GH production via the pituitary; BPC-157 works through growth factor and NO pathways; GLP-1 agonists work through incretin receptors). Growth hormone secretagogues do not suppress the HPG axis, do not cause virilization, and have a substantially different safety profile. Some peptides (particularly GH secretagogues) are prohibited by WADA in competitive sports due to performance effects, but this is a regulatory classification, not a toxicity equivalence to steroids.
How is BPC-157 different from other healing supplements?
BPC-157 differs from standard supplements in several important ways: (1) it is a specific amino acid sequence (synthetic peptide) rather than a plant extract, vitamin, or mineral — its activity depends on the exact sequence and structure; (2) it works through receptor-mediated signaling pathways (VEGFR2, nitric oxide, EGF receptor) rather than providing substrate for biochemical reactions; (3) it has targeted biological effects in wound healing, angiogenesis, and gut repair confirmed in hundreds of animal studies — a level of mechanistic evidence exceeding most supplements; (4) it requires either injection or oral administration (oral form is primarily for gut effects, injection for systemic effects due to limited oral peptide bioavailability); (5) it is not currently FDA-approved for any indication and is considered a research compound — practitioners who use it are doing so based on the preclinical evidence and clinical experience, not FDA approval.
What are the risks of semaglutide for weight loss?
Semaglutide (Wegovy 2.4mg weekly) produces average weight loss of 15–17% of body weight (STEP 1 trial, n=1,961, 68 weeks: 15.3% vs. 2.4% placebo). The primary risks: (1) Muscle loss — accelerated weight loss without adequate protein intake and resistance training causes preferential lean mass loss; the clinical protocol requires high-protein diet (1.2–1.6g/kg body weight daily) and progressive resistance training 2-3x/week; (2) GLP-1 withdrawal and rebound — weight is regained rapidly upon cessation in most patients (SELECT trial data confirms this is a chronic therapy requiring continuation for sustained benefit); (3) Gastrointestinal effects — nausea, vomiting, constipation particularly during dose escalation; managed by slow titration over 4–6 months; (4) Gallbladder disease — 2.6% vs. 1.2% gallbladder events in STEP trials; (5) Rare pancreatitis — monitoring amylase/lipase if symptoms occur; (6) Thyroid C-cell tumors — seen in rodent studies (but rodents have 40x more GLP-1 receptors on thyroid C-cells than humans); current clinical consensus: not contraindicated in patients with no personal/family history of medullary thyroid carcinoma or MEN2.
How do growth hormone secretagogue peptides compare to actual HGH injections?
Growth hormone secretagogues (GHS like CJC-1295/Ipamorelin) and exogenous recombinant HGH (somatropin) produce different GH patterns with different risk profiles. Exogenous HGH: non-pulsatile delivery produces supraphysiologic GH with sustained IGF-1 elevation — effective but associated with: fluid retention, carpal tunnel syndrome, joint pain, insulin resistance (continuous GH antagonizes insulin signaling), and theoretical acromegaly-like effects at high doses. GHS: preserve pulsatile GH secretion with normal inter-pulse nadir periods — this preserves the metabolic benefits of GH pulsatility while reducing the side effects of continuous high GH levels. GHS are also self-limiting — the body’s own GH feedback mechanisms (somatostatin release in response to high GH) prevent runaway GH excess. Cost differential is dramatic: pharmaceutical HGH is $500–$2,000+/month; compounded GHS peptides (when available) were $50–$150/month. The FDA’s 2023–2024 compounding restrictions have significantly limited GHS accessibility in the U.S.
To schedule a comprehensive peptide therapy consultation at The Private Practice, call (810) 206-1402 or visit theprivatepractice.co. We provide medically supervised peptide protocols with appropriate baseline evaluation, ongoing monitoring, and integration with comprehensive functional medicine optimization.